Published in J Mol Biomark Diagn on November 14, 2014
Monitoring serum HER2 levels in breast cancer patients. Springerplus (2015) 0.81
Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One (2016) 0.76
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer (2007) 2.84
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene (1987) 2.67
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res (1998) 1.57
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
p95HER2 and breast cancer. Cancer Res (2011) 1.38
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem (2003) 1.32
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther (2006) 1.23
A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol (1993) 1.20
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res (2011) 1.19
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res (2007) 1.06
Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution. Proc Natl Acad Sci U S A (2001) 1.05
A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat Med (2006) 1.03
HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev (2011) 1.02
IL-8 and cathepsin B as melanoma serum biomarkers. Int J Mol Sci (2011) 1.00
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene (2008) 0.99
Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene (2001) 0.92
Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta (2012) 0.91
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Res (2013) 0.87
HER2 and hormone receptor-positive breast cancer--blocking the right target. Nat Rev Clin Oncol (2010) 0.85
Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat (1996) 0.84
c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori (2006) 0.83
Non-specific immunoglobulin interactions may lead to false-positive results in assays for human anti-mouse monoclonal antibodies (HAMA). J Immunoassay (1992) 0.81
erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prev (1994) 0.79